On June 26, 2012 Navidea Biopharmaceuticals, Inc. announced that it has elected to continue its diligence through the end of July 2012 with the Alseres Pharmaceuticals, Inc. to license E-IAFCT Injection (CFT), also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson's disease and movement disorders. The option agreement Navidea entered into in January 2012 with the Alseres Pharmaceuticals provided Navidea with exclusive rights through July 31, 2012 to perform final due diligence and prepare the documentation necessary to enter into a definitive license agreement for CFT. Under the terms of the option agreement, Navidea paid Alseres an option fee of $500,000 for the exclusive right to negotiate a definitive license agreement by June 30, 2012. However, the option agreement also provided Navidea the right to extend the option period from June 30, 2012, to July 31, 2012, for an additional $250,000 which would be due upon execution of a definitive license, if completed. The option agreement anticipates that Navidea will issue Alseres 400,000 shares of Navidea common stock upon execution of the definitive license agreement. The option also anticipates that the license agreement will provide for contingent milestone payments of up to $3.0 million, $2.75 million of which will principally occur at the time of product registration or upon commercial sales, and the issuance of up to an additional 1.05 million shares of Navidea stock, 950,000 shares of which are issuable at the time of product registration or upon commercial sales. In addition, the license terms outlined in the option agreement anticipate royalties on net sales of the approved product which are consistent with industry-standard terms.